We are in the midst of a scientific renaissance in neurodegeneration, driven by growing evidence of overarching biological processes that drive neurodegenerative disorders.
Our ambition at Janssen is to become a leader in neurodegeneration. We are working to develop innovations for a diverse range of patients, from large, clinically diverse populations. This work begins with research and development, where we have potentially transformational early science in Alzheimer’s disease and Parkinson’s disease.